These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38730115)

  • 1. Anti-Drug Antibody Incidence Comparison of Therapeutic Proteins Administered Via Subcutaneous vs. Intravenous Route.
    Felderman J; Ramaiah L; Vazquez-Abad MD; Messing D; Chen Y
    AAPS J; 2024 May; 26(3):60. PubMed ID: 38730115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins.
    Hamuro L; Kijanka G; Kinderman F; Kropshofer H; Bu DX; Zepeda M; Jawa V
    J Pharm Sci; 2017 Oct; 106(10):2946-2954. PubMed ID: 28576695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world evidence and patient preference for subcutaneous
    Gold R; Schmidt S; Deisenhammer F; Motte J; Richter N; Taipale K; Salmen HC; Bohland C; Schirduan K
    Ther Adv Neurol Disord; 2024; 17():17562864241241382. PubMed ID: 38616781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats.
    Srinivas NR; Shyu WC; Weiner RS; Warner G; Comereski C; Tay LK; Greene DS; Barbhaiya RH
    Pharm Res; 1997 Jul; 14(7):911-6. PubMed ID: 9244149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
    Burmester GR; Choy E; Kivitz A; Ogata A; Bao M; Nomura A; Lacey S; Pei J; Reiss W; Pethoe-Schramm A; Mallalieu NL; Wallace T; Michalska M; Birnboeck H; Stubenrauch K; Genovese MC
    Ann Rheum Dis; 2017 Jun; 76(6):1078-1085. PubMed ID: 28007755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Pharmacology Approaches to Support Approval of New Routes of Administration for Therapeutic Proteins.
    Wang YC; Ji P; Hariharan S; Wang J; Okusanya O; AbuAsal B; Zhu H; Madabushi R; Huang SM; Zineh I
    Clin Pharmacol Ther; 2024 Mar; 115(3):440-451. PubMed ID: 38235832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review.
    Van den Nest M; Glechner A; Gold M; Gartlehner G
    Syst Rev; 2019 Dec; 8(1):321. PubMed ID: 31829250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy.
    Penny HL; Hainline K; Theoharis N; Wu B; Brandl C; Webhofer C; McComb M; Wittemer-Rump S; Koca G; Stienen S; Bargou RC; Hummel HD; Loidl W; Grüllich C; Eggert T; Tran B; Mytych DT
    Front Immunol; 2023; 14():1261070. PubMed ID: 37942314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models.
    Liu B; Jones M; Kong L; Noel T; Jeng EK; Shi S; England CG; Alter S; Miller JS; Cai W; Rhode PR; Wong HC
    Cytokine; 2018 Jul; 107():105-112. PubMed ID: 29452720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW; Roth D; Gordon D; Struemper H
    Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of tanezumab following intravenous or subcutaneous administration to patients with osteoarthritis or chronic low back pain.
    Shoji S; Suzuki A; Gaitonde P; Cai CH; Marshall S
    Br J Clin Pharmacol; 2022 Jul; 88(7):3321-3334. PubMed ID: 35112378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials.
    Suleiman AA; Minocha M; Khatri A; Pang Y; Othman AA
    Clin Pharmacokinet; 2019 Oct; 58(10):1309-1321. PubMed ID: 31054118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis.
    Bril V; Lampe J; Cooper N; Kiessling P; Gardulf A
    J Comp Eff Res; 2024 Sep; 13(9):e230171. PubMed ID: 39115099
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunogenicity of Atezolizumab: Influence of Testing Method and Sampling Frequency on Reported Anti-drug Antibody Incidence Rates.
    Usdin M; Quarmby V; Zanghi J; Bernaards C; Liao L; Laxamana J; Wu B; Swanson S; Song Y; Siguenza P
    AAPS J; 2024 Jul; 26(4):84. PubMed ID: 39009791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit.
    Alten R; An Y; Kim DH; Yoon S; Peyrin-Biroulet L
    Clin Drug Investig; 2022 Jun; 42(6):477-489. PubMed ID: 35657560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy.
    Minarik J; Pavlicek P; Pour L; Pika T; Maisnar V; Spicka I; Jarkovsky J; Krejci M; Bacovsky J; Radocha J; Straub J; Kessler P; Wrobel M; Walterova L; Sykora M; Obernauerova J; Brozova L; Gregora E; Adamova D; Gumulec J; Adam Z; Scudla V; Hajek R;
    PLoS One; 2015; 10(4):e0123866. PubMed ID: 25875484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine.
    Pederson S; Biondi DM; Allan B; Cady R; Schaeffler B; Baker B; Latham J
    Front Immunol; 2021; 12():765822. PubMed ID: 34759933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Immunogenicity of Frunevetmab in Osteoarthritic Cats Following Intravenous and Subcutaneous Administration.
    Walters RR; Boucher JF; De Toni F
    Front Vet Sci; 2021; 8():687448. PubMed ID: 34179175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics.
    Davda J; Declerck P; Hu-Lieskovan S; Hickling TP; Jacobs IA; Chou J; Salek-Ardakani S; Kraynov E
    J Immunother Cancer; 2019 Apr; 7(1):105. PubMed ID: 30992085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.